Skip to main content

Amoclan Disease Interactions

There are 7 disease interactions with Amoclan (amoxicillin / clavulanate).


Amoxicillin-clavulanate (applies to Amoclan) hepatotoxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The administration of amoxicillin-clavulanate has infrequently been associated with hepatotoxicity such as elevations in serum transaminases, bilirubin, and/or alkaline phosphatase. The histologic findings on liver biopsy have consisted of predominantly cholestatic and/or hepatocellular changes. Symptoms may occur during or several weeks after therapy. The hepatotoxicity is generally reversible, although deaths have been reported on rare occasions, mostly in patients with serious underlying diseases or concomitant use of other medications. Liver enzyme abnormalities have also been observed with the use of amoxicillin or ampicillin alone. According to the manufacturer, therapy with amoxicillin-clavulanate should be administered cautiously in patients with evidence of hepatic dysfunction. Periodic monitoring of liver function is recommended during prolonged therapy. The use of amoxicillin-clavulanate is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with the drug.


  1. Dowsett JF, Gillow T, Heagerty A, Radcliffe M, Toadi R, Isle I, Russell RC (1989) "Amoxycillin/clavulanic acid (augmentin)-induced intrahepatic cholestasis." Dig Dis Sci, 34, p. 1290-3
  2. Verhamme M, Ramboer C, Van De Bruaene P, Inderadjaja N (1989) "Cholestatic hepatitis due to an amoxycillin/clavulanic acid preparation." J Hepatol, 9, p. 260-4
  3. Wong FS, Ryan J, Dabkowski P, Dudley FJ, Sewell RB, Smallwood RA (1991) "Augmentin-induced jaundice." Med J Aust, 154, p. 698-701
  4. Hebbard GS, Smith KG, Gibson PR, Bhathal PS (1992) "Augmentin-induced jaundice with a fatal outcome." Med J Aust, 156, p. 285-6
  5. Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M (1992) "Granulomatous hepatitis due to combination of amoxacillin and clavulanic acid." Dig Dis Sci, 37, p. 150-2
  6. Larrey D, Vial T, Micaleff A, et al. (1992) "Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases." Gut, 33, p. 368-71
  7. (2002) "Product Information. Augmentin (amoxicillin-clavulanate)." SmithKline Beecham
  8. Habior A, Walewskazielecka B, Butruk E (1994) "Hepatocellular-cholestatic liver injury due to amoxycillin-clavulanic acid combination." Clin Investig, 72, p. 616-8
  9. Thomson JA, Fairley CK, Ugoni AM, Forbes AB, Purcell PM, Desmond PV, Smallwood RA, Mcneil JJ (1995) "Risk factors for the development of amoxycillin-clavulanic acid associated jaundice." Med J Aust, 162, p. 638-40
  10. Ryley NG, Fleming KA, Chapman RWG (1995) "Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (augmentin)." J Hepatol, 23, p. 278-82
  11. Friess G, Wienbeck M (1995) "Cholestatic jaundice after taking amoxicillin and clavulanic acid." Dtsch Med Wochenschr, 120, p. 1356-60
  12. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ (1996) "Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid" Arch Intern Med, 156, p. 1327-32
  13. Limauro DL, ChanTompkins NH, Carter RW, Brodmerkel GJ, Agrawal RM (1999) "Amoxicillin/clavulanate-associated hepatic failure with progression to Stevens-Johnson syndrome." Ann Pharmacother, 33, p. 560-4
View all 13 references

Antibiotics (applies to Amoclan) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.


  1. (2002) "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories
  2. (2002) "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome
  3. (2002) "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome
  4. (2002) "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn
  5. (2002) "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals
  6. (2002) "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals
  7. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham
  8. (2001) "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals
  9. (2001) "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis
  10. (2001) "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn
  11. (2003) "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc
  12. (2004) "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals
  13. (2007) "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical
  14. (2009) "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc
  15. (2009) "Product Information. Vibativ (telavancin)." Theravance Inc
  16. (2010) "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals
  17. (2022) "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc
  18. (2014) "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.
  19. (2014) "Product Information. Orbactiv (oritavancin)." The Medicines Company
  20. (2017) "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions
  21. (2017) "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.
  22. (2022) "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC
  23. (2018) "Product Information. Zemdri (plazomicin)." Achaogen
  24. (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
  25. (2018) "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.
  26. (2018) "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.
  27. (2019) "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc
  28. (2019) "Product Information. Biaxin (clarithromycin)." AbbVie US LLC, SUPPL-61
  29. (2021) "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group, LAB-0372-7.0
  30. (2018) "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals, SUPPL-74
  31. (2020) "Product Information. Priftin (rifapentine)." sanofi-aventis, SUPPL-18
  32. (2021) "Product Information. Xerava (eravacycline)." Tetraphase Pharmaceuticals, Inc
  33. (2023) "Product Information. Xacduro (durlobactam-sulbactam)." La Jolla Pharmaceutical
  34. (2024) "Product Information. Exblifep (cefepime-enmetazobactam)." Allecra Therapeutics
  35. (2021) "Product Information. Maxipime (cefepime)." Hospira Inc, SUPPL-46
View all 35 references

Aminopenicillins (applies to Amoclan) mononucleosis

Moderate Potential Hazard, Moderate plausibility.

Patients with mononucleosis treated with an aminopenicillin antibiotic, may develop a pruritic erythematous maculopapular skin rash. The rash is usually self-limiting and resolves within days of discontinuing the offending agent. An altered drug metabolism or an immune-mediated process unrelated to drug hypersensitivity has been proposed as the underlying mechanism. Therapy with aminopenicillin antibiotics should not be administered in patients with mononucleosis.


  1. "Product Information. Polycillin-PRB (ampicillin-probenecid)." Apothecon Inc
  2. (2002) "Product Information. Spectrobid (bacampicillin)." Roerig Division
  3. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham

Amoxicillin (applies to Amoclan) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using Clinitest®, Benedict's Solution or Fehling's Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix®) be used.


  1. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham

Amoxicillin (applies to Amoclan) PKU

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Phenylketonuria

Some amoxicillin chewable tablets and suspensions products contain phenylalanine. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).


  1. (2002) "Product Information. Augmentin (amoxicillin-clavulanate)." SmithKline Beecham

Beta-lactams (oral) (applies to Amoclan) renal dysfunction

Moderate Potential Hazard, High plausibility.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function. Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.


  1. Bergan T (1978) "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother, 13, p. 971-4
  2. Ehrnebo M, Nilsson SO, Boreus LO (1979) "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm, 7, p. 429-51
  3. Humbert G, Spyker DA, Fillastre JP, Leroy A (1979) "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother, 15, p. 28-33
  4. Bloch R, Szwed JJ, Sloan RS, Luft FC (1977) "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother, 12, p. 730-2
  5. Santoro J, Agarwal BN, Martinelli R, et al. (1978) "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother, 13, p. 951-4
  6. Spyker DA, Thomas BL, Sande MA, Bolton WK (1978) "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother, 14, p. 172-7
  7. Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E (1979) "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother, 5, p. 465-70
  8. Fillastre JP, Leroy A, Humbert G, Godin M (1980) "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother, 6, p. 155-6
  9. Berman SJ, Boughton WH, Sugihara JG, et al. (1978) "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother, 14, p. 281-3
  10. Spyker DA, Gober LL, Scheld WM, et al. (1982) "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother, 21, p. 278-81
  11. Pommer W, Krause PH, Berg PA, et al. (1986) "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr, 64, p. 290-3
  12. Guay DR, Meatherall RC, Harding GK, Brown GR (1986) "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother, 30, p. 485-90
  13. Dhib M, Moulin B, Leroy A, et al. (1991) "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol, 41, p. 579-83
  14. Shyu WC, Pittman KA, Wilber RB, et al. (1991) "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol, 31, p. 362-71
  15. Humbert G, Leroy A, Fillastre JP, Godin M (1979) "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy, 25, p. 189-95
  16. Leroy A, Humbert G, Godin M, Fillastre JP (1982) "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother, 10, p. 39-46
  17. Kabins SA, Kelner B, Walton E, Goldstein E (1970) "Cephalexin therapy as related to renal function." Am J Med Sci, 259, p. 133-42
  18. Kunin CM, Finkelberg Z (1970) "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med, 72, p. 349-56
  19. Yamasaku F, Tsuchida R, Usuda Y (1970) "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J, Suppl, p. 57-9
  20. Bailey RR, Gower PE, Dash CH (1970) "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J, 46, p. 60-4
  21. Regamey C, Humair L (1971) "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J, 47 Supp), p. 69-77
  22. Reisberg BE, Mandelbaum JM (1971) "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun, 3, p. 540-3
  23. Kirby WM, de Maine JB, Serrill WS (1971) "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J, 47 Suppl, p. 41-6
  24. Brogard JM, Pinget M, Dorner M, Lavillaureix J (1975) "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol, 15, p. 666-73
  25. Chow M, Quintiliani R, Cunha BA, et al. (1979) "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol, 19, p. 185-94
  26. Finkelstein ER, Quintiliani R, Nightingale CH (1978) "Pharmacokinetics of oral cephalosporins." J Pediatr, 93, p. 902
  27. Andriole VT (1978) "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis, 137, s88-99
  28. Hori R, Okumura K, Nihira H, et al. (1985) "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther, 38, p. 290-5
  29. St Peter JV, Borin MT, Hughes GS, et al. (1992) "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother, 36, p. 126-31
  30. Gibaldi M, Perrier D (1972) "Drug distribution and renal failure." J Clin Pharmacol, 12, p. 201-4
  31. Hoffman TA, Cestero R, Bullock WE (1970) "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med, 73, p. 173-8
  32. Latos DL, Bryan CS, Stone WJ (1975) "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther, 17, p. 692-700
  33. Arancibia A, Droguett MT, Fuentes G, et al. (1982) "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol, 20, p. 447-53
  34. Sjovall J, Westerlund D, Alvan G (1985) "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol, 19, p. 191-201
  35. Jackson EA, McLeod DC (1974) "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm, 31, p. 36-52
  36. Bailey RR, Eastwood JB, Vaughan RB (1972) "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J, 48, p. 422-5
  37. Nelson JD, Reimold EW (1973) "Carbenicillin pharmacokinetics in an anephric patient." Lancet, 1, p. 486-7
  38. Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H (1977) "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy, 23, p. 299-308
  39. Hoffler D, Koeppe P, Corcilius M, Przyklink A (1990) "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection, 18, p. 157-62
  40. Yamasaku F, Tsuchida R, Usada Y (1970) "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J, Suppl, p. 57-9
  41. Standiford HC, Jordan MC, Kirby WM (1970) "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis, 122, s9-13
  42. Andriole VT (1978) "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis, 137, s88-97
  43. Schwinghammer TL, Norden CW, Gill E (1990) "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol, 30, p. 893-9
  44. Solomon AE, Briggs JD (1975) "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol, 2, p. 443-8
  45. Neu HC (1981) "The pharmacokinetics of bacampicillin." Rev Infect Dis, 3, p. 110-6
  46. Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G (1981) "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther, 4, p. 32-42
  47. DeSante KA, Zeckel ML (1992) "Pharmacokinetic profile of loracarbef." Am J Med, 92, s16-9
  48. "Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.
  49. (2002) "Product Information. Spectrobid (bacampicillin)." Roerig Division
  50. (2002) "Product Information. Geocillin (carbenicillin)." Roerig Division
  51. (2002) "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company
  52. (2002) "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb
  53. (2002) "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc
  54. (2002) "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn
  55. (2002) "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb
  56. (2002) "Product Information. Keflex (cephalexin)." Dista Products Company
  57. (2002) "Product Information. Velosef (cephradine)." Apothecon Inc
  58. (2002) "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company
  59. Therasse DG, Farlow DS, Davidson RL, et al. (1993) "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther, 54, p. 311-6
  60. Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE (1994) "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos, 22, p. 447-50
  61. Hyslop DL (1988) "Cefaclor safety profile: a ten-year review." Clin Ther, 11 Suppl A, p. 83-94
  62. (2001) "Product Information. Amoxil (amoxicillin)." SmithKline Beecham
  63. (2001) "Product Information. Cedax (ceftibuten)." Schering-Plough
  64. Nix DE, Symonds WT, Hyatt JM, et al. (1997) "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy, 17, p. 121-5
  65. (2001) "Product Information. Omnicef (cefdinir)." Parke-Davis
  66. Guay DRP (1997) "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother, 31, p. 1022-33
  67. (2001) "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc
  68. (2024) "Product Information. Pivya (pivmecillinam)." UTILITY Therapeutics Ltd
View all 68 references

Penicillins (applies to Amoclan) hemodialysis

Moderate Potential Hazard, High plausibility.

Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.


  1. Giron JA, Meyers BR, Hirschman SZ, Srulevitch E (1981) "Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother, 19, p. 279-83
  2. Heim KL (1985) "The effect of hemodialysis on piperacillin pharmacokinetics." Drug Intell Clin Pharm, 19, p. 455
  3. Francke EL, Appel GB, Neu HC (1979) "Kinetics of intravenous amoxicillin in patients on long-term dialysis." Clin Pharmacol Ther, 26, p. 31-5
  4. Slaughter RL, Kohli R, Brass C (1984) "Effects of hemodialysis on the pharmacokinetics of amoxicillin/clavulanic acid combination." Ther Drug Monit, 6, p. 424-7
  5. Janicke DM, Mangione A, Schultz RW, Jusko WJ (1981) "Mezlocillin disposition in chronic hemodialysis patients." Antimicrob Agents Chemother, 20, p. 590-4
  6. Kampf D, Schurig R, Weihermuller K, Forster D (1980) "Effects of impaired renal function hemodialysis and peritoneal dialysis on the pharmacokinetics of mezlocillin." Antimicrob Agents Chemother, 18, p. 81-7
  7. Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (1988) "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of augmentin." Br J Clin Pharmacol, 26, p. 385-90
  8. Francke E, Mehta S, Neu HC, Appel GB (1979) "Kinetics of intravenous mezlocillin in chronic hemodialysis patients." Clin Pharmacol Ther, 26, p. 228-31
  9. Thorsteinsson SB, Steingrimsson O, Asmundsson P, Bergan T (1981) "Pharmacokinetics of mezlocillin during haemodialysis." Scand J Infect Dis, 29, p. 59-63
  10. Wise R, Reeves DS, Parker AS (1974) "Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis." Antimicrob Agents Chemother, 5, p. 119-20
  11. Brogard JM, Comte F, Spach MO, Lavillaureix J (1982) "Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function." Chemotherapy, 28, p. 318-26
  12. Oe PL, Simonian S, Verhoef J (1973) "Pharmacokinetics of the new penicillins." Chemotherapy, 19, p. 279-88
  13. Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ (1988) "Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother, 32, p. 503-9
  14. Blum RA, Kohli RK, Harrison NJ, Schentag JJ (1989) "Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother, 33, p. 1470-6
  15. Rho JP, Jones A, Wood M, et al. (1989) "Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects." J Antimicrob Chemother, 24, p. 573-80
  16. "Product Information. Polycillin-PRB (ampicillin-probenecid)." Apothecon Inc
  17. (2002) "Product Information. Spectrobid (bacampicillin)." Roerig Division
  18. (2002) "Product Information. Geocillin (carbenicillin)." Roerig Division
  19. (2002) "Product Information. Mezlin (mezlocillin)." Bayer
  20. (2001) "Product Information. Pfizerpen (penicillin)." Roerig Division
  21. (2001) "Product Information. Pipracil (piperacillin)." Lederle Laboratories
  22. (2001) "Product Information. Ticar (ticarcillin)." SmithKline Beecham
View all 22 references

Amoclan drug interactions

There are 71 drug interactions with Amoclan (amoxicillin / clavulanate).

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.